Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
Filing tables
Filing exhibits
- 10-K Annual report
- 4.12 EX-4.12
- 10.2 EX-10.2
- 10.17 EX-10.17
- 10.19 EX-10.19
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23
- 10.32 EX-10.32
- 10.35 EX-10.35
- 10.36 EX-10.36
- 10.37 EX-10.37
- 10.38 EX-10.38
- 10.39 EX-10.39
- 21.1 EX-21.1
- 23.1 EX-23.1
- 31.1 EX-31.1
- 31.2 EX-31.2
- 32.1 EX-32.1
- 32.2 EX-32.2
- Download Excel data file
- View Excel data file
Related press release
Associated XFOR transcripts
XFOR similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Paula Ragan, Ph.D., certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge, the Annual Report on Form 10-K of X4 Pharmaceuticals, Inc. for the fiscal year ended December 31, 2019 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-K fairly presents, in all material respects, the financial condition and results of operations of X4 Pharmaceuticals, Inc.
/s/ Paula Ragan, Ph.D. | ||
Name: Paula Ragan, Ph.D. | ||
Title: President, Chief Executive Officer and Secretary | ||
(Principal Executive Officer) |
March 12, 2020 | |||||